trending Market Intelligence /marketintelligence/en/news-insights/trending/uyvmkldbsx98ynsynp8ymw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

GSK drops out of race for Pfizer's $20B consumer healthcare arm

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

GSK drops out of race for Pfizer's $20B consumer healthcare arm

GlaxoSmithKline Plc said it pulled out from the bidding battle to acquire Pfizer Inc.'s consumer healthcare business valued at $20 billion.

"While we will continue to review opportunities that may accelerate our strategy, they must meet our criteria for returns and not compromise our priorities for capital allocation," GSK CEO Emma Walmsley said in a news release.

According to recent reports, the British drugmaker was leading the auction for the Pfizer division, which sells branded over-the-counter products. Reckitt Benckiser Group Plc, which was only looking to acquire part of the business, also withdrew from the sale process.

GlaxoSmithKline shares were up 3.72% to £13.21 apiece as of 8:10 a.m. London time March 23.